Lifestyle Intervention in Patients With Metastatic Prostate Cancer

Studien-Informationen Einschlusskriterien Studien-Rationale Geprüfte Regime

Rekrutierend

NCT-Nummer:
NCT05850182

Studienbeginn:
November 2023

Letztes Update:
05.04.2024

Wirkstoff:
-

Indikation (Clinical Trials):
Prostatic Neoplasms

Geschlecht:
Männer

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
Oncology Institute of Southern Switzerland

Collaborator:
-

Kontakt

Ursula Vogl, MD
Kontakt:
Phone: +41 91 811 84 63
E-Mail: ursula.vogl@eoc.ch» Kontaktdaten anzeigen

Luigi Tortola, PhD
Kontakt:
Phone: +41 91 811 96 68
E-Mail: luigi.tortola@eoc.ch» Kontaktdaten anzeigen

Studienlocations
(1 von 1)

Oncology Institute of Southern Switzerland (IOSI)
6500 Bellinzona
SwitzerlandRekrutierend» Google-Maps
Ansprechpartner:
Ursula Vogl, MD
Phone: +41 91 811 84 63
E-Mail: ursula.vogl@eoc.ch

Luigi Tortola, PhD
Phone: +41 91 811 96 68
E-Mail: luigi.tortola@eoc.ch» Ansprechpartner anzeigen

Studien-Informationen

Detailed Description:

Prostate cancer (PCa) is among the most frequent tumor types and is the second deadliest type

of cancer in men.

PCa has a multifactorial aetiology; modifiable environmental factors, including diet and

obesity, have been associated with prostate carcinogenesis. Furthermore, patients with PCa

are treated with androgen deprivation therapy (ADT), which has negative effects on the

cardiovascular system and body composition, particularly on the fat and muscle mass, bone

health and psychological wellbeing.

Data in the current literature suggests that a lifestyle intervention e.g. with targeted and

supervised exercise therapy or a dietary intervention with a prudent dietary patternmay

positively influence the quality of life and the course of the disease of patients under ADT.

However, conclusive data is missing.

The proposed pilot study aims at determining the feasibility and the effect of a lifestyle

intervention including adherence to a personalised dietary regimen combined with regular

physical activity in patients newly diagnosed with PCa under ADT.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Written informed consent according to ICH/GCP regulations before registration.

- Age ≥ 18 years

- Histology of adenocarcinoma of the prostate

- Patients with PCa receiving ADT alone or ADT+NHT (abiraterone, enzalutamide,

apalutamide or darolutamide)

- Rising PSA (two consecutively rising PSA levels > 25% above nadir at least three weeks

apart), with no evidence of clinical or radiographic progression on instrumental

evaluation

- PSA doubling time > 8 weeks

- Continuation of ongoing systemic treatment is deemed feasible by treating physician

Exclusion Criteria:

- Ongoing treatment with docetaxel, cabazitaxel, radionuclides or investigational

treatments

- Evidence of clinical progression or progression of disease on imaging

- Bone metastases excluding the safety of physical exercise

- Prior confirmed severe osteoporosis or other diseases affecting the bone with history

of fractures

- Clinically significant cardiovascular disease (i.e. myocardial infarction within 6

months before screening; uncontrolled angina within 3 months before screening;

congestive heart failure New York Heart Association class 3 or 4; history of

clinically significant arrhythmias; uncontrolled hypertension indicated by systolic

blood pressure > 170 mm Hg or diastolic blood pressure > 105 mm Hg at screening)

- Clinically significant chronic obstructive pulmonary disease

- Any concurrent disease or comorbid condition that interferes with the ability of the

patient to participate in the study

Studien-Rationale

Primary outcome:

1. Patient initiation rate (Time Frame - 12 weeks):
Study initiation rate (total number of patients enrolled divided by the number of patients screened for the study)

2. Patient retention rate (Time Frame - 12 weeks):
Retention rate (number of patients completing the study divided by total number of patients enrolled at baseline)

3. Adherence to prescribed training program (Time Frame - 12 weeks):
Adherence rate (fraction of scheduled physical activity appointments/selftrainings attended/carried out by the patients)

4. Adherence to prescribed dietary regimen (Time Frame - 12 weeks):
Adherence rate (fraction of days of adherence to the prescribed dietary regimen)

Secondary outcome:

1. Effect of lifestyle intervention on PSA progression (Time Frame - 24 weeks):
Percentage of PSA non-progressors (patients with <25% PSA rise compared to baseline) at weeks 8, 12 and 24

2. Effect of lifestyle intervention on PSA levels (Time Frame - 24 weeks):
PSA doubling time calculated with the formula PSA doubling time = ln (2) / PSA Slope [PSA Slope = (ln (PSA level 2) - ln (PSA level 1)) / Time (no. of months)]

3. Effect of lifestyle intervention on radiographic progression (Time Frame - 24 weeks):
Percentage of patients being free of radiographic progression according to PCWG3 at weeks 12 and 24

4. Effect of lifestyle intervention on patient-reported quality of life (Time Frame - 24 weeks):
Change in patient-reported quality of life from baseline using Functional Assessment of Cancer Therapy - Prostate (FACT-P) scoring from baseline to weeks 8, 12 and 24

5. Effect of lifestyle intervention on patient-reported fatigue (Time Frame - 24 weeks):
Change in patient-reported fatigue from baseline using FACIT Fatigue scoring from baseline to weeks 8, 12 and 24

6. Effect of lifestyle intervention on time to subsequent treatment (Time Frame - 24 months):
Time to a subsequent line of treatment (in weeks)

7. Effect of lifestyle intervention on plasma lipid signature (Time Frame - 8 weeks):
Concentration of individual lipid types in the plasma of participating patients, change compared to baseline

8. Effect of lifestyle intervention on plasma immune signature (Time Frame - 8 weeks):
Concentration of inflammatory cytokines in the plasma of participating patients, change compared to baseline

9. Effect of lifestyle intervention on microbiome composition (Time Frame - 8 weeks):
Differences in community diversity and/or abundance of specific bacterial taxa within the intestinal microbiome prior to or during the lifestyle intervention.

10. Effect of lifestyle intervention on anthropometric variables (Time Frame - 24 weeks):
Measurement of patient height and body weight and calculation of body-mass index (BMI) at baseline, during and after the lifesyle intervention.

11. Effect of lifestyle intervention on lean body mass (Time Frame - 12 weeks):
Measurement of the percentage of lean body mass by bioelectrical impedance vector analysis and by magnetic resonance imaging.

12. Effect of lifestyle intervention on fat body mass (Time Frame - 12 weeks):
Measurement of the percentage of fat body mass by bioelectrical impedance vector analysis and by magnetic resonance imaging.

Geprüfte Regime

Lifestyle intervention:
12-week lifestyle intervention including adherence to a personalized balanced dietary regimen (low total fat, low saturated fat, high ω3 fatty acids, optimized protein content, low simple sugars) combined with regular physical activity (including physiotherapy sessions and self-training).

Quelle: ClinicalTrials.gov

Sie können folgenden Inhalt einem Kollegen empfehlen:

"Lifestyle Intervention in Patients With Metastatic Prostate Cancer"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!